| scholarly article | Q13442814 |
| P50 | author | Timothy D. McHugh | Q42114088 |
| Helen McIlleron | Q48287171 | ||
| Hennie Geldenhuys | Q56998680 | ||
| Salome Charalambous | Q60648422 | ||
| Mark Hatherill | Q76888530 | ||
| Gavin J Churchyard | Q81693193 | ||
| P2093 | author name string | David Coleman | |
| Patrick P J Phillips | |||
| Stanley Mungofa | |||
| Philip D Butcher | |||
| Janneke H van Dijk | |||
| Thomas S Harrison | |||
| Simbarashe P Zvada | |||
| James Shepherd | |||
| Amina Jindani | |||
| Andrew J Nunn | |||
| Sambayawo Nyirenda | |||
| Simukai Zizhou | |||
| Anna L E Bateson | |||
| Denny A Mitchison | |||
| Heather E Clouting | |||
| Lloyd Magweta | |||
| Nasir A Shah | |||
| RIFAQUIN Trial Team | |||
| P2860 | cites work | Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model | Q21144660 |
| Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications | Q28146009 | ||
| Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice | Q28364123 | ||
| Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum | Q28472502 | ||
| Practical guidelines for multiplicity adjustment in clinical trials. | Q30327667 | ||
| Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers | Q34045240 | ||
| Multiplicity in randomised trials II: subgroup and interim analyses | Q34417512 | ||
| Potent twice-weekly rifapentine-containing regimens in murine tuberculosis | Q35776635 | ||
| A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project | Q36483331 | ||
| Chest radiograph reading and recording system: evaluation for tuberculosis screening in patients with advanced HIV. | Q36825344 | ||
| Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial. | Q38492327 | ||
| Combination antifungal therapy for cryptococcal meningitis | Q41924502 | ||
| Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine | Q41962727 | ||
| Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial | Q42683018 | ||
| Timing of relapse in short-course chemotherapy trials for tuberculosis. | Q43488989 | ||
| Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. | Q45089281 | ||
| Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. | Q46029821 | ||
| Multiplicity in randomised trials I: endpoints and treatments. | Q53622606 | ||
| Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium | Q64131862 | ||
| Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report | Q74630346 | ||
| Development and evaluation of a new chest radiograph reading and recording system for epidemiological surveys of tuberculosis and lung disease | Q81360033 | ||
| Pharmacokinetic/pharmacodynamic parameters and the choice of high-dosage rifamycins | Q84572163 | ||
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | tuberculosis | Q12204 |
| moxifloxacin | Q424940 | ||
| rifapentine | Q3935297 | ||
| pulmonary tuberculosis | Q13046587 | ||
| P304 | page(s) | 1599-1608 | |
| P577 | publication date | 2014-10-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | High-dose rifapentine with moxifloxacin for pulmonary tuberculosis | |
| P478 | volume | 371 |
| Q50170378 | A Bayesian response-adaptive trial in tuberculosis: The endTB trial. |
| Q36012300 | A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis |
| Q39456569 | A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis |
| Q53791744 | A Step toward an Optimized Rifampin Dose Completed. |
| Q46046130 | A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens |
| Q111441936 | A multi-scale pipeline linking drug transcriptomics with pharmacokinetics predicts in vivo interactions of tuberculosis drugs |
| Q28602112 | A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP) |
| Q58569877 | A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis |
| Q35745991 | A sterilizing tuberculosis treatment regimen is associated with faster clearance of bacteria in cavitary lesions in marmosets |
| Q58569805 | A stratified approach to tuberculosis treatment |
| Q41257028 | Activity of lipophilic and hydrophilic drugs against dormant and replicating Mycobacterium tuberculosis. |
| Q36243425 | Advances in basic and translational tuberculosis research: Proceedings of the first meeting of RePORT international |
| Q64063422 | Advances in clinical trial design for development of new TB treatments: A call for innovation |
| Q34466861 | Advancing host-directed therapy for tuberculosis |
| Q91650393 | Advancing the development of new tuberculosis treatment regimens: The essential role of translational and clinical pharmacology and microbiology |
| Q53800201 | Anything to Stay Alive: The Challenges of a Campaign for an Experimental Drug. |
| Q62487449 | Arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of Rifapentine: a population pharmacokinetics analysis |
| Q28384421 | Assessment of treatment response in tuberculosis |
| Q52671395 | Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis. |
| Q38386950 | Bedaquiline for the treatment of drug-resistant tuberculosis |
| Q35742479 | Bibliometric Assessment of European and Sub-Saharan African Research Output on Poverty-Related and Neglected Infectious Diseases from 2003 to 2011. |
| Q91710448 | Both Pharmacokinetic Variability and Granuloma Heterogeneity Impact the Ability of the First-Line Antibiotics to Sterilize Tuberculosis Granulomas |
| Q92572142 | Building a tuberculosis-free world: The Lancet Commission on tuberculosis |
| Q30251933 | Challenges in the clinical assessment of novel tuberculosis drugs. |
| Q47888089 | Choice between Levofloxacin and Moxifloxacin and Multidrug-Resistant Tuberculosis Treatment Outcomes. |
| Q89820519 | Clinical Development of New TB Vaccines: Recent Advances and Next Steps |
| Q64136742 | Clinically prevalent mutations in Mycobacterium tuberculosis alter propionate metabolism and mediate multidrug tolerance |
| Q48309955 | Combinations of registered drugs reduce treatment times required to deplete Wolbachia in the Litomosoides sigmodontis mouse model. |
| Q38619965 | Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach. |
| Q53699940 | Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention. |
| Q28075252 | Current strategies to treat tuberculosis |
| Q28069032 | Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis |
| Q53805600 | DOOR/RADAR: A Gateway Into the Unknown? |
| Q38906215 | Defining dormancy in mycobacterial disease. |
| Q91828649 | Designing noninferiority tuberculosis treatment trials: Identifying practical advantages for drug regimens with acceptable effectiveness |
| Q50097384 | Detecting Phenotypically Resistant Mycobacterium tuberculosis Using Wavelength Modulated Raman Spectroscopy |
| Q35960935 | Determination of bedaquiline in human serum using liquid chromatography-tandem mass spectrometry |
| Q93030583 | Developing new TB biomarkers, are miRNA the answer? |
| Q64135045 | Diabetes mellitus comorbidity in patients enrolled in tuberculosis drug efficacy trials around the world: A systematic review |
| Q65002838 | Diagnostic Delays and Treatment Implications for Patients with Isoniazid-Resistant Tuberculosis: A Case Report and Review of the Literature. |
| Q59793187 | Differentially Detectable Mycobacterium tuberculosis Cells in Sputum from Treatment-Naive Subjects in Haiti and Their Proportionate Increase after Initiation of Treatment |
| Q28388018 | Driving the Way to Tuberculosis Elimination: The Essential Role of Fundamental Research |
| Q33801345 | Drug-resistant tuberculosis and advances in the treatment of childhood tuberculosis |
| Q40498114 | Early Biomarkers and Regulatory Innovation in Multidrug-Resistant Tuberculosis |
| Q38973113 | Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB. |
| Q26775757 | Effects of Fluroquinolones in Newly Diagnosed, Sputum-Positive Tuberculosis Therapy: A Systematic Review and Network Meta-Analysis |
| Q89315356 | Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial |
| Q33810454 | Efficacy of ultra-short course chemotherapy for new smear positive drug susceptible pulmonary tuberculosis: study protocol of a multicenter randomized controlled clinical trial |
| Q49792134 | Elevated Plasma Moxifloxacin Concentrations and SLCO1B1 g.-11187G>A Polymorphism in Adults with Pulmonary Tuberculosis |
| Q54996259 | Emergence and selection of isoniazid and rifampin resistance in tuberculosis granulomas. |
| Q38724073 | Emerging drugs and alternative possibilities in the treatment of tuberculosis |
| Q26771997 | Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations? |
| Q89997582 | Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations |
| Q60335601 | Evaluation of a medication monitor-based treatment strategy for drug-sensitive tuberculosis patients in China: study protocol for a cluster randomised controlled trial |
| Q36115081 | Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial |
| Q41280396 | Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models |
| Q47139711 | Evaluation of serum inflammatory biomarkers as predictors of treatment outcome in pulmonary tuberculosis. |
| Q49193526 | Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum |
| Q92446178 | Feasibility of Direct Sputum Molecular Testing for Drug Resistance as Part of Tuberculosis Clinical Trials Eligibility Screening |
| Q36253299 | Finding the right dose of rifampicin, and the right dose of optimism |
| Q33165650 | Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study |
| Q91902659 | Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations |
| Q92351388 | Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance |
| Q57452818 | Gender differences in tuberculosis treatment outcomes: a post hoc analysis of the REMoxTB study |
| Q37358635 | Genomic Analysis of the Evolution of Fluoroquinolone Resistance in Mycobacterium tuberculosis Prior to Tuberculosis Diagnosis. |
| Q33595994 | Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance |
| Q93221164 | High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease |
| Q41085601 | Host-Directed Therapies for Tackling Multi-Drug Resistant Tuberculosis: Learning From the Pasteur-Bechamp Debates |
| Q64091498 | How Can Operational Research Help to Eliminate Tuberculosis in the Asia Pacific Region? |
| Q61805077 | Humanized Mouse Model Mimicking Pathology of Human Tuberculosis for Evaluation of Drug Regimens |
| Q35867681 | Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial. |
| Q38777021 | Improved power for TB Phase IIa trials using a model-based pharmacokinetic-pharmacodynamic approach compared with commonly used analysis methods. |
| Q38378647 | Improving the tuberculosis drug development pipeline |
| Q28607283 | In silico evaluation and exploration of antibiotic tuberculosis treatment regimens |
| Q92638344 | Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons |
| Q41249313 | Infectious disease. More than just bugs in spit. |
| Q38965421 | Inhibiting Mycobacterium tuberculosis within and without |
| Q26749428 | Integrated therapy for HIV and tuberculosis |
| Q90701813 | Intracellular Pharmacodynamic Modeling Is Predictive of the Clinical Activity of Fluoroquinolones against Tuberculosis |
| Q92589365 | Isoniazid Concentration and NAT2 Genotype Predict Risk of Systemic Drug Reactions during 3HP for LTBI |
| Q64063419 | Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape |
| Q40075546 | Label-free optical vibrational spectroscopy to detect the metabolic state of M. tuberculosis cells at the site of disease. |
| Q40672103 | Latent tuberculosis |
| Q38564576 | Latent tuberculosis in kidney and liver transplant patients: a review of treatment practices and outcomes. |
| Q35915044 | Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials |
| Q98178575 | Longitudinal Pharmacokinetic-Pharmacodynamic Biomarkers Correlate With Treatment Outcome in Drug-Sensitive Pulmonary Tuberculosis: A Population Pharmacokinetic-Pharmacodynamic Analysis |
| Q38848891 | Mathematical Models of Tuberculosis Reactivation and Relapse |
| Q35617686 | Month 2 culture status and treatment duration as predictors of recurrence in pulmonary tuberculosis: model validation and update |
| Q36650622 | Moxifloxacin and gatifloxacin for initial therapy of tuberculosis: a meta-analysis of randomized clinical trials |
| Q52584723 | Moxifloxacin replacement in contemporary tuberculosis drug regimens is ineffective against persistent Mycobacterium tuberculosis: Novel insights from the Cornell mouse model. |
| Q38387116 | Mycobacterium tuberculosis: 2014 Clinical trials in review |
| Q40087530 | NOS2-deficient mice with hypoxic necrotizing lung lesions predict outcomes of tuberculosis chemotherapy in humans |
| Q26741138 | New Antituberculosis Drugs: From Clinical Trial to Programmatic Use |
| Q38754367 | New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment Response |
| Q47594312 | New antituberculous drugs derived from natural products: current perspectives and issues in antituberculous drug development |
| Q40578494 | Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. |
| Q49825374 | Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria |
| Q28391110 | Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure |
| Q36094215 | Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines |
| Q35718241 | Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis |
| Q40192322 | Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis |
| Q60364149 | Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs |
| Q47332682 | Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization? |
| Q52606539 | Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data. |
| Q57490086 | Phenotypic Changes on Mycobacterium Tuberculosis-Specific CD4 T Cells as Surrogate Markers for Tuberculosis Treatment Efficacy |
| Q36729961 | Phenotypically Adapted Mycobacterium tuberculosis Populations from Sputum Are Tolerant to First-Line Drugs |
| Q37270722 | Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project |
| Q30379233 | Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model |
| Q91620177 | Projecting the impact of variable MDR-TB transmission efficiency on long-term epidemic trends in South Africa and Vietnam |
| Q50285140 | Quality of reporting of outcomes in phase III studies of pulmonary tuberculosis: a systematic review |
| Q50862469 | Quantifying the impact of drug combination regimens on TB treatment efficacy and multidrug resistance probability. |
| Q89630590 | Quantitative 18F-FDG PET-CT scan characteristics correlate with tuberculosis treatment response |
| Q90131019 | Re-growth of Mycobacterium tuberculosis populations exposed to antibiotic combinations is due to the presence of isoniazid and not bacterial growth rate |
| Q94687169 | Real-time monitoring of live mycobacteria with a microfluidic acoustic-Raman platform |
| Q28085210 | Recent Developments and Future Opportunities in the Treatment of Tuberculosis in Children |
| Q35763405 | Respiratory Infections in the U.S. Military: Recent Experience and Control |
| Q40095703 | Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis? |
| Q38857578 | Rifamycins, Alone and in Combination |
| Q38933165 | Rifapentine for the treatment of latent tuberculosis |
| Q104286463 | Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial |
| Q36907876 | Serial image analysis of Mycobacterium tuberculosis colony growth reveals a persistent subpopulation in sputum during treatment of pulmonary TB |
| Q35901882 | Shortened first-line TB treatment in Brazil: potential cost savings for patients and health services |
| Q57775011 | Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis |
| Q91906541 | Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis |
| Q40363572 | Shortening Tuberculosis Treatment With Fluoroquinolones: Lost in Translation? |
| Q41444380 | Shortening treatment of tuberculosis: lessons from fluoroquinolone trials. |
| Q53691502 | Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial. |
| Q46747793 | Simultaneous staining of sputum smears for acid-fast and lipid-containing Myobacterium tuberculosis can enhance the clinical evaluation of antituberculosis treatments |
| Q30901894 | Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies |
| Q46252989 | Sputum culture conversion as a tuberculosis biomarker: a glass half empty or half full? |
| Q46418555 | Sputum culture conversion in new TB regimens |
| Q93379521 | Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial |
| Q37640769 | Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: study protocol for a prospective, multicenter, randomized, open-label, phase II trial |
| Q26771848 | Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2 |
| Q46478240 | Targeting DNA Replication and Repair for the Development of Novel Therapeutics against Tuberculosis |
| Q28553119 | The Effectiveness and Safety of Fluoroquinolone-Containing Regimen as a First-Line Treatment for Drug-Sensitive Pulmonary Tuberculosis: A Systematic Review and Meta-Analysis |
| Q90159634 | The Genetic Background Modulates the Evolution of Fluoroquinolone-Resistance in Mycobacterium tuberculosis |
| Q64240244 | The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019 |
| Q64249398 | The TAM-TB Assay-A Promising TB Immune-Diagnostic Test With a Potential for Treatment Monitoring |
| Q64898975 | The Use of Fluoroquinolones for Tuberculosis in Victoria between 2011 and 2016. |
| Q38617197 | The anti-tuberculosis agents under development and the challenges ahead |
| Q35765601 | The association between sterilizing activity and drug distribution into tuberculosis lesions |
| Q28598393 | The best of respiratory infections from the 2015 European Respiratory Society International Congress |
| Q36350734 | The effectiveness of sputum pH analysis in the prediction of response to therapy in patients with pulmonary tuberculosis |
| Q57152709 | The importance of clinical pharmacokinetic-pharmacodynamic studies in unraveling the determinants of early and late tuberculosis outcomes |
| Q35815071 | The need to accelerate access to new drugs for multidrug-resistant tuberculosis |
| Q38676708 | The paradigm shift to end tuberculosis. Are we ready to assume the changes? |
| Q60914138 | The present state of the tuberculosis drug development pipeline |
| Q35624245 | The role of delamanid in the treatment of drug-resistant tuberculosis |
| Q26765372 | The role of moxifloxacin in tuberculosis therapy |
| Q41987253 | Time to Sputum Culture Conversion and Treatment Outcomes Among Patients with Isoniazid-Resistant Tuberculosis in Atlanta, Georgia |
| Q56969466 | Toxicity associated with tuberculosis chemotherapy in the REMoxTB study |
| Q60364153 | Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges |
| Q36094210 | Translating the Tuberculosis Research Agenda: Much Accomplished, but Much More to Be Done |
| Q26765051 | Translational Research for Tuberculosis Elimination: Priorities, Challenges, and Actions |
| Q42281128 | Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes. |
| Q26801605 | Treatment of Drug Susceptible Pulmonary Tuberculosis |
| Q90044060 | Treatment of Highly Drug-Resistant Pulmonary Tuberculosis |
| Q59352498 | Treatment of drug-susceptible tuberculosis among people living with human immunodeficiency virus infection: an update |
| Q40885391 | Treatment of tuberculosis. Current standards |
| Q60047408 | Treatment outcomes for isoniazid-monoresistant tuberculosis in Peru, 2012-2014 |
| Q57235679 | Tuberculosis |
| Q59200569 | Tuberculosis |
| Q92572130 | Tuberculosis |
| Q26741141 | Tuberculosis Biomarkers: From Diagnosis to Protection |
| Q35584122 | Tuberculosis control strategies to reach the 2035 global targets in China: the role of changing demographics and reactivation disease |
| Q63363709 | Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization |
| Q38378992 | Tuberculosis treatment and management--an update on treatment regimens, trials, new drugs, and adjunct therapies |
| Q38795742 | Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers |
| Q47159580 | Tuberculosis: Just the FAQs |
| Q26738604 | Tuberculous pleural effusion |
| Q47739307 | University of Pennsylvania 8th annual conference on statistical issues in clinical trials: Pragmatic clinical trials (morning panel). |
| Q33735642 | Update in Mycobacterium tuberculosis lung disease 2014. |
| Q53384520 | Use of fluoroquinolones for the treatment of TB: 8 years of experience. |
| Q36325978 | Use of whole-genome sequencing to distinguish relapse from reinfection in a completed tuberculosis clinical trial |
| Q57276328 | Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial |
| Q30249635 | What are the most efficacious treatment regimens for isoniazid-resistant tuberculosis? A systematic review and network meta-analysis. |
| Q27304811 | World TB Day 2016: an interview with leading experts in tuberculosis research |
Search more.